GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Long-Term Debt

Nyrada (ASX:NYR) Long-Term Debt : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Long-Term Debt?

Nyrada's Long-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Nyrada Long-Term Debt Historical Data

The historical data trend for Nyrada's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Long-Term Debt Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Long-Term Debt
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Debt Get a 7-Day Free Trial - - - - -

Nyrada  (ASX:NYR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Nyrada Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Nyrada's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada (ASX:NYR) Business Description

Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines